TG Therapeutics Inc (NASDAQ:TGTX) Short Interest Decreased By 11.83%

July 14, 2018 - By Adrian Erickson

Investors sentiment decreased to 1.46 in Q1 2018. Its down 0.54, from 2 in 2017Q4. It turned negative, as 11 investors sold TG Therapeutics, Inc. shares while 30 reduced holdings. 29 funds opened positions while 31 raised stakes. 37.47 million shares or 6.47% more from 35.20 million shares in 2017Q4 were reported.
Federated Invsts Pa accumulated 57,539 shares. Senzar Asset Management Ltd Liability has 2.13% invested in TG Therapeutics, Inc. (NASDAQ:TGTX). Ny State Common Retirement Fund reported 103,653 shares stake. Pura Vida Invests Limited Liability Corp accumulated 0% or 50,000 shares. Moreover, Geode Mngmt Ltd Limited Liability Company has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 498,251 shares. Raymond James & Associates holds 0.01% or 226,017 shares. Highland Management Limited Partnership invested in 464,391 shares or 0.34% of the stock. Barclays Pcl invested in 23,304 shares. Millennium Mngmt Limited Co, a New York-based fund reported 389,990 shares. Ghost Tree Capital Lc holds 0.86% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX) for 300,000 shares. Moreover, Columbus Circle Investors has 0.22% invested in TG Therapeutics, Inc. (NASDAQ:TGTX). Raymond James Advsrs holds 0.01% or 139,071 shares. Voya Mngmt Limited Liability Corporation invested in 0% or 22,521 shares. Gp Inc One Trading Lp has invested 0.02% in TG Therapeutics, Inc. (NASDAQ:TGTX). Cibc Ww Markets Inc accumulated 33,450 shares or 0% of the stock.

Since June 14, 2018, it had 0 insider buys, and 2 insider sales for $960,508 activity. Power Sean A sold 47,191 shares worth $623,303.

The stock of TG Therapeutics Inc (NASDAQ:TGTX) registered a decrease of 11.83% in short interest. TGTX’s total short interest was 10.71M shares in July as published by FINRA. Its down 11.83% from 12.15M shares, reported previously. With 873,400 shares average volume, it will take short sellers 12 days to cover their TGTX’s short positions. The short interest to TG Therapeutics Inc’s float is 25.28%.

The stock increased 0.37% or $0.05 during the last trading session, reaching $13.45. About 623,196 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 14.71% since July 14, 2017 and is uptrending. It has outperformed by 2.14% the S&P500.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $1.04 billion. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin??s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

TG Therapeutics, Inc. (NASDAQ:TGTX) Ratings Coverage

Among 3 analysts covering TG Therapeutics (NASDAQ:TGTX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 6 analyst reports since January 17, 2018 according to SRatingsIntel. Raymond James maintained the stock with “Buy” rating in Thursday, April 19 report. On Wednesday, March 21 the stock rating was initiated by H.C. Wainwright with “Buy”. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by FBR Capital on Wednesday, January 17. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by FBR Capital on Monday, June 4. FBR Capital maintained TG Therapeutics, Inc. (NASDAQ:TGTX) on Friday, March 9 with “Buy” rating. FBR Capital maintained the shares of TGTX in report on Friday, February 2 with “Buy” rating.

More news for TG Therapeutics, Inc. (NASDAQ:TGTX) were recently published by:, which released: “Trillium up 13% premarket” on June 21, 2018.‘s article titled: “Your Daily Pharma Scoop: TG Therapeutics Phase 2 Results, Geron Positive, Agio In Phase 3” and published on June 20, 2018 is yet another important article.

TG Therapeutics, Inc. (NASDAQ:TGTX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.